TY - JOUR
T1 - Impact of HLA Mismatch Direction on the Outcome of Unrelated Bone Marrow Transplantation
T2 - A Retrospective Analysis from the Japan Society for Hematopoietic Cell Transplantation
AU - HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation
AU - Kanda, Junya
AU - Ichinohe, Tatsuo
AU - Fuji, Shigeo
AU - Maeda, Yoshinobu
AU - Ohashi, Kazuteru
AU - Fukuda, Takahiro
AU - Miyamura, Koichi
AU - Iwato, Koji
AU - Eto, Tetsuya
AU - Nakamae, Hirohisa
AU - Kobayashi, Naoki
AU - Mori, Takehiko
AU - Mori, Shin Ichiro
AU - Morishima, Yasuo
AU - Atsuta, Yoshiko
AU - Kanda, Yoshinobu
N1 - Funding Information:
Financial disclosure: This work was supported in part by the Japan Leukemia Research Fund (to J.K.).
Publisher Copyright:
© 2015 American Society for Blood and Marrow Transplantation.
PY - 2015/2/1
Y1 - 2015/2/1
N2 - The relative desirability of an unrelated donor with a bidirectional 1-locus mismatch (1MM-Bi), a 1-locus mismatch only in the graft-versus-host direction (1MM-GVH), or a 1-locus mismatch only in the host-versus-graft direction (1MM-HVG) is not yet clear. We analyzed adult patients with leukemia or myelodysplastic syndrome who received a first allogeneic stem cell transplant from an HLA-A, -B, -C, and -DRB1 matched or 1-allele mismatched unrelated donor in Japan. The effects of 1MM-Bi (n= 1020), 1MM-GVH (n= 83), and 1MM-HVG (n= 83) compared with a zero mismatch (0MM) (n= 2570) were analyzed after adjusting for other significant variables. The risk of grades III to IV acute graft-versus-host disease (GVHD) was higher with marginal significance in the 1MM-GVH group than in the 0MM group (hazard ratio, 1.85; P=.014). However, there was no significant difference in overall or nonrelapse mortality between the 1MM-GVH and 0MM groups. There was no significant difference in acute GVHD or overall or nonrelapse mortality between the 1MM-HVG and 0MM groups. The risks of acute GVHD and overall mortality were significantly higher in the 1MM-Bi group than in the 0MM group. These findings indicate that unrelated donors with 1MM-GVH and 1MM-HVG are both good candidates for patients without an HLA-matched unrelated donor in a Japanese cohort.
AB - The relative desirability of an unrelated donor with a bidirectional 1-locus mismatch (1MM-Bi), a 1-locus mismatch only in the graft-versus-host direction (1MM-GVH), or a 1-locus mismatch only in the host-versus-graft direction (1MM-HVG) is not yet clear. We analyzed adult patients with leukemia or myelodysplastic syndrome who received a first allogeneic stem cell transplant from an HLA-A, -B, -C, and -DRB1 matched or 1-allele mismatched unrelated donor in Japan. The effects of 1MM-Bi (n= 1020), 1MM-GVH (n= 83), and 1MM-HVG (n= 83) compared with a zero mismatch (0MM) (n= 2570) were analyzed after adjusting for other significant variables. The risk of grades III to IV acute graft-versus-host disease (GVHD) was higher with marginal significance in the 1MM-GVH group than in the 0MM group (hazard ratio, 1.85; P=.014). However, there was no significant difference in overall or nonrelapse mortality between the 1MM-GVH and 0MM groups. There was no significant difference in acute GVHD or overall or nonrelapse mortality between the 1MM-HVG and 0MM groups. The risks of acute GVHD and overall mortality were significantly higher in the 1MM-Bi group than in the 0MM group. These findings indicate that unrelated donors with 1MM-GVH and 1MM-HVG are both good candidates for patients without an HLA-matched unrelated donor in a Japanese cohort.
KW - Donor selection
KW - GVHD
KW - Graft-versus-host direction
KW - HLA mismatch
KW - Host-versus-graft direction
KW - Overall survival
UR - http://www.scopus.com/inward/record.url?scp=84920931740&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84920931740&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2014.10.015
DO - 10.1016/j.bbmt.2014.10.015
M3 - Article
C2 - 25464119
AN - SCOPUS:84920931740
SN - 1083-8791
VL - 21
SP - 305
EP - 311
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 2
ER -